Compare · ABT vs ACAD
ABT vs ACAD
Side-by-side comparison of Abbott Laboratories (ABT) and ACADIA Pharmaceuticals Inc. (ACAD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ACAD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 43.0x ACAD ($3.69B).
- Over the past year, ABT is down 31.7% and ACAD is down 3.3% - ACAD leads by 28.4 points.
- ACAD has been more active in the news (9 items in the past 4 weeks vs 5 for ABT).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- ACADIA Pharmaceuticals Inc.
- Price
- $91.06+0.38%
- $21.56-0.71%
- Market cap
- $158.63B
- $3.69B
- 1M return
- +5.60%
- +0.47%
- 1Y return
- -31.73%
- -3.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1985
- News (4w)
- 5
- 9
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Latest ABT
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
Latest ACAD
- Director Baker Bros. Advisors Lp was granted 37,244 shares (SEC Form 4)
- Director Harrigan Edmund converted options into 8,107 shares, increasing direct ownership by 23% to 43,148 units (SEC Form 4)
- Director Ndu Adora converted options into 8,107 shares, increasing direct ownership by 33% to 32,908 units (SEC Form 4)
- Director Daly James M converted options into 8,107 shares, increasing direct ownership by 201% to 12,148 units (SEC Form 4)
- Director Brege Laura converted options into 8,107 shares, increasing direct ownership by 54% to 23,202 units (SEC Form 4)
- Director Garofalo Elizabeth A. converted options into 8,107 shares, increasing direct ownership by 32% to 33,489 units (SEC Form 4)
- Director Poole Jonathan converted options into 2,010 shares (SEC Form 4)
- ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- PRINCIPAL ACCOUNTING OFFICER Kihara James sold $114,393 worth of shares (5,401 units at $21.18), decreasing direct ownership by 18% to 24,509 units (SEC Form 4)
- SEC Form 10-Q filed by ACADIA Pharmaceuticals Inc.